Zobrazeno 1 - 10
of 153
pro vyhledávání: '"Andries M Bergman"'
Autor:
Sander AL Palit, Daniel Vis, Suzan Stelloo, Cor Lieftink, Stefan Prekovic, Elise Bekers, Ingrid Hofland, Tonći Šuštić, Liesanne Wolters, Roderick Beijersbergen, Andries M Bergman, Balázs Győrffy, Lodewyk FA Wessels, Wilbert Zwart, Michiel S van der Heijden
Publikováno v:
eLife, Vol 8 (2019)
Androgen receptor (AR) inhibitors represent the mainstay of prostate cancer treatment. In a genome-wide CRISPR-Cas9 screen using LNCaP prostate cancer cells, loss of co-repressor TLE3 conferred resistance to AR antagonists apalutamide and enzalutamid
Externí odkaz:
https://doaj.org/article/caac5d360d0a4963af4d216fca34abf4
Autor:
Maisa N. G. van Genderen, Jeroen Kneppers, Anniek Zaalberg, Elise M. Bekers, Andries M. Bergman, Wilbert Zwart, Federica Eduati
Publikováno v:
npj Systems Biology and Applications, Vol 10, Iss 1, Pp 1-13 (2024)
Abstract Inhibiting androgen receptor (AR) signaling through androgen deprivation therapy (ADT) reduces prostate cancer (PCa) growth in virtually all patients, but response may be temporary, in which case resistance develops, ultimately leading to le
Externí odkaz:
https://doaj.org/article/ccd027487f2c48e3a61d12b40884f5e4
Autor:
Stefan A.J. Buck, Marinda Meertens, Frederiek M.F. van Ooijen, Esther Oomen-de Hoop, Evert de Jonge, Marieke J.H. Coenen, Andries M. Bergman, Stijn L.W. Koolen, Ronald de Wit, Alwin D.R. Huitema, Ron H.N. van Schaik, Ron H.J. Mathijssen
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 169, Iss , Pp 115890- (2023)
Extragonadal androgens play a pivotal role in prostate cancer disease progression on androgen receptor signaling inhibitors (ARSi), including abiraterone and enzalutamide. We aimed to investigate if germline variants in genes involved in extragonadal
Externí odkaz:
https://doaj.org/article/6d3d5ec4ff3b487a8575fbe70cc76c22
Autor:
Niven Mehra, Iris Kloots, Michiel Vlaming, Shafak Aluwini, Els Dewulf, Daniela E. Oprea-Lager, Henk van der Poel, Herman Stoevelaar, Derya Yakar, Chris H. Bangma, Elise Bekers, Roderick van den Bergh, Andries M. Bergman, Franchette van den Berkmortel, Steve Boudewijns, Winand N.M. Dinjens, Jurgen Fütterer, Tom van der Hulle, Guido Jenster, Leonie I. Kroeze, Michel van Kruchten, Geert van Leenders, Pim J. van Leeuwen, Wendy W.J. de Leng, R. Jeroen A. van Moorselaar, Walter Noordzij, Rogier A. Oldenburg, Inge M. van Oort, Irma Oving, Jack A. Schalken, Ivo G. Schoots, Ed Schuuring, Robert J. Smeenk, Ben G.L. Vanneste, Erik Vegt, André N. Vis, Kim de Vries, Peter-Paul M. Willemse, Maurits Wondergem, Margreet Ausems
Publikováno v:
European Urology Open Science, Vol 49, Iss , Pp 23-31 (2023)
Background: Germline and tumour genetic testing in prostate cancer (PCa) is becoming more broadly accepted, but testing indications and clinical consequences for carriers in each disease stage are not yet well defined. Objective: To determine the con
Externí odkaz:
https://doaj.org/article/6f52ae4fdd99475585e6ab93b18449bb
Autor:
Jeroen Kneppers, Tesa M. Severson, Joseph C. Siefert, Pieter Schol, Stacey E. P. Joosten, Ivan Pak Lok Yu, Chia-Chi Flora Huang, Tunç Morova, Umut Berkay Altıntaş, Claudia Giambartolomei, Ji-Heui Seo, Sylvan C. Baca, Isa Carneiro, Eldon Emberly, Bogdan Pasaniuc, Carmen Jerónimo, Rui Henrique, Matthew L. Freedman, Lodewyk F. A. Wessels, Nathan A. Lack, Andries M. Bergman, Wilbert Zwart
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-16 (2022)
Epigenetic reprogramming of the androgen receptor (AR) has been identified as an important process driving prostate cancer (PCa) progression. Here, the authors analyze the role of AR chromatin binding heterogeneity in PCa clinical outcomes, metastasi
Externí odkaz:
https://doaj.org/article/391fd7851a8744c0932eb78127f219b4
Publikováno v:
European Urology Open Science, Vol 48, Iss , Pp 98-100 (2023)
Testosterone measurements are essential in the management of patients with prostate cancer undergoing castration and androgen deprivation therapy. There has been an ongoing discussion on the testosterone castration cutoff (TCC), with the primary focu
Externí odkaz:
https://doaj.org/article/524dbf8ae50e423abd45403c29568329
Autor:
Bastiaan M. Privé, Marcel J. R. Janssen, Inge M. van Oort, Constantijn H. J. Muselaers, Marianne A. Jonker, Willemijn A. van Gemert, Michel de Groot, Harm Westdorp, Niven Mehra, J. Fred Verzijlbergen, Tom W. J. Scheenen, Patrik Zámecnik, Jelle O. Barentsz, Martin Gotthardt, Walter Noordzij, Wouter V. Vogel, Andries M. Bergman, Henk G. van der Poel, André N. Vis, Daniela E. Oprea-Lager, Winald R. Gerritsen, J. Alfred Witjes, James Nagarajah
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-4 (2021)
Abstract Background The BULLSEYE trial is a multicenter, open-label, randomized controlled trial to test the hypothesis if 177Lu-PSMA is an effective treatment in oligometastatic hormone-sensitive prostate cancer (oHSPC) to prolong the progression-fr
Externí odkaz:
https://doaj.org/article/d0eae2f7bc184b94b9f6863ede0c30e8
Autor:
Meixia Che, Aashi Chaturvedi, Sarah A. Munro, Samuel P. Pitzen, Alex Ling, Weijie Zhang, Josh Mentzer, Sheng-Yu Ku, Loredana Puca, Yanyun Zhu, Andries M. Bergman, Tesa M. Severson, Colleen Forster, Yuzhen Liu, Jacob Hildebrand, Mark Daniel, Ting-You Wang, Luke A. Selth, Theresa Hickey, Amina Zoubeidi, Martin Gleave, Rohan Bareja, Andrea Sboner, Wayne Tilley, Jason S. Carroll, Winston Tan, Manish Kohli, Rendong Yang, Andrew C. Hsieh, Paari Murugan, Wilbert Zwart, Himisha Beltran, R. Stephanie Huang, Scott M. Dehm
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
While many treatments for prostate cancer suppress the androgen receptor it becomes reactivated during disease progression. Here, the authors show that a KLF5 transcriptional programme is also activated during treatment and promotes migration and the
Externí odkaz:
https://doaj.org/article/0d96a02002f9414c84ce1f8008d43a91
Autor:
Tesa M. Severson, Yanyun Zhu, Angelo M. De Marzo, Tracy Jones, Jonathan W. Simons, William G. Nelson, Srinivasan Yegnasubramanian, Matthew L. Freedman, Lodewyk Wessels, Andries M. Bergman, Michael C. Haffner, Wilbert Zwart
Publikováno v:
Molecular Oncology, Vol 15, Iss 7, Pp 1942-1955 (2021)
The epigenomic regulation of transcriptional programs in metastatic prostate cancer is poorly understood. We studied the epigenomic landscape of prostate cancer drivers using transcriptional profiling and ChIP‐seq in four clonal metastatic tumors d
Externí odkaz:
https://doaj.org/article/56b5db94e7bb424f9f026fc02defd139
Autor:
Sander A. L. Palit, Jeroen van Dorp, Daniel Vis, Cor Lieftink, Simon Linder, Roderick Beijersbergen, Andries M. Bergman, Wilbert Zwart, Michiel S. van der Heijden
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Abstract Resistance to drugs targeting the androgen receptor (AR) signaling axis remains an important challenge in the treatment of prostate cancer patients. Activation of alternative growth pathways is one mechanism used by cancer cells to prolifera
Externí odkaz:
https://doaj.org/article/397d23f9500a43ac881b9b8bb5c1a817